The patent fight over CRISPR is like a high-stakes poker game with a dose of caveat emptor for investors. “Investors in biotech darn well know that this is fraught with investment danger,” said Paul Leiman, who teaches the business law of biotechnology at Johns Hopkins University’s Carey Business School.
Source: The Battle Over CRISPR Could Make Or Break Some Biotech Companies | FiveThirtyEight
Insight Sciences 